PHNO [(+)‐4‐propyl‐9‐hydroxynaphthoxazine]
- 1 October 1988
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 38 (10) , 1541
- https://doi.org/10.1212/wnl.38.10.1541
Abstract
PHNO [(+)-4-propyl-9-hydroxynaphthoxazine] is a chemically novel and highly potent dopamine (D2) receptor agonist without D1 activity. It had significant antiparkinsonism effects when used as open-label monotherapy in ten patients who were Hoehn and Yahr stage 2 or 3. The standard formulation of PHNO produced a 3- to 4-hour therapeutic effect in most patients; the response to the time-release formulation lasted up to 10 hours. Side effects were similar to those of other dopamine agonists but dyskinesia was seen in only one patient.This publication has 4 references indexed in Scilit:
- A Short Test of Mental Status: Description and Preliminary ResultsMayo Clinic Proceedings, 1987
- (+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISMThe Lancet, 1985
- PHARMACOLOGIC PROFILE OF A NOVEL POTENT DIRECT-ACTING DOPAMINE AGONIST, "(+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE [(+)-PHNO]1984
- ParkinsonismNeurology, 1967